

# Juliet C Gray

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5101752/juliet-c-gray-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28

papers

468

citations

11

h-index

21

g-index

35

ext. papers

603

ext. citations

6.9

avg, IF

3.05

L-index

#	Paper	IF	Citations
28	Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments. <b>2022</b> , 10,		2
27	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , <b>2020</b> , 127, 52-66	7.5	26
26	Immune characterization of pre-clinical murine models of neuroblastoma. <i>Scientific Reports</i> , <b>2020</b> , 10, 16695	4.9	5
25	Immune reconstitution in children following chemotherapy for acute leukemia. <i>EJHaem</i> , <b>2020</b> , 1, 142-150.	0.9	2
24	PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?. <i>Cancer Letters</i> , <b>2019</b> , 457, 74-85	9.9	9
23	PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer. <i>Archives of Disease in Childhood</i> , <b>2019</b> , 104, 25-29	2.2	5
22	Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front-line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 10014-10014	2.2	7
21	Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 10014-10014	2.2	3
20	Hypercalcaemia secondary to ectopic parathyroid hormone expression in an adolescent with metastatic alveolar rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e26778	3	4
19	Immunotherapy with anti-GD2 antibody ch14.18/CHO-IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10539-10539	2.2	5
18	Overview of Monoclonal Antibody Therapies <b>2018</b> , 65-78		1
17	Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 <sup>+</sup> T Cell Effector Function. <i>Immunity</i> , <b>2018</b> , 49, 958-970.e7	32.3	72
16	Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. <i>Cancers</i> , <b>2018</b> , 10,	6.6	8
15	Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 111-111	2.2	
14	Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10500-10500	2.2	14
13	Correlation of killer-cell Ig-like receptor (KIR) haplotypes and Fcγ-receptor polymorphisms with survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10548-10548	2.2	2
12	Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10562-10562	2.2	2

11	PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. <i>OncImmunity</i> , <b>2015</b> , 4, e1029701	7.2	40
10	Mutations in the transcriptional repressor REST predispose to Wilms tumor. <i>Nature Genetics</i> , <b>2015</b> , 47, 1471-4	36.3	36
9	Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy. <i>Pediatric Blood and Cancer</i> , <b>2015</b> , 62, 1317-25	3	11
8	Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 559-69	7.4	5
7	Narcolepsy with cataplexy as presenting symptom of occult neuroblastoma. <i>Pediatric Neurology</i> , <b>2013</b> , 49, 64-7	2.9	5
6	Hepatoblastoma in a child with a paternally-inherited ABCC8 mutation and mosaic paternal uniparental disomy 11p causing focal congenital hyperinsulinism. <i>European Journal of Medical Genetics</i> , <b>2013</b> , 56, 114-7	2.6	16
5	Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3545-55 <sup>12.9</sup>	12.9	30
4	Immunotherapy for neuroblastoma: turning promise into reality. <i>Pediatric Blood and Cancer</i> , <b>2009</b> , 53, 931-40	3	13
3	Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. <i>European Journal of Immunology</i> , <b>2008</b> , 38, 2499-511	6.1	46
2	Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. <i>Blood</i> , <b>2007</b> , 109, 4810-5	2.2	83
1	Therapeutic potential of immunostimulatory monoclonal antibodies. <i>Clinical Science</i> , <b>2006</b> , 111, 93-106	6.5	13